Risk assessment of amyloidogenic segments by way of transfection

R. Kingi made this Official Information request to Ministry of Health

The request was refused by Ministry of Health.

From: R. Kingi

Dear Ministry of Health,

Several papers have been published on amyloidogenic or prionergic segments of the sars-cov2 spike protein (e.g. "Amyloidogenesis of SARS-CoV-2 Spike Protein", J. Am. Chem. Soc., 2022, 144, 20, 8945–8950, https://pubs.acs.org/doi/10.1021/jacs.2c...). These epitopes also occur as a consequence of the expression the pfizer injectable products, such as bnt162b2.

Of note is that the spike from expression of the pfizer injectable can be detected in some individuals for quite some time (see "Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms", ProteomicsClin.Appl.2023;17:2300048, https://onlinelibrary.wiley.com/doi/10.1...)

Given that, I request any internal reports, notes, communications or risk assessments related to the expression of these amyloidogenic or prionergic segments by way of commercial product, such as bnt162b2.

Yours faithfully,

R. Kingi

Link to this

From: OIA Requests


Attachment image.png
80K Download


Kia ora
  
Thank you for your request for official information. The reference number
for your request is: H2023034061
  
As required under the Official Information Act 1982, Manatū Hauora will
endeavour to respond to your request no later than 20 working days after
the day your request was received. However, over the holiday period there
are 3 weeks that don’t count as ‘working days’. For Official Information
Act (OIA) requests, the holiday period is 25 December 2022 to 15 January
2023 (inclusive). This affects OIA requests received on or after 27
November 2022. If you'd like to calculate the timeframe, you can use the
Ombudsman's online calculator
here: [1]http://www.ombudsman.parliament.nz/  
  
If you have any queries, please feel free to contact the OIA Services Team
on [2][email address]. If any additional factors come to light which
are relevant to your request, please do not hesitate to contact us so that
these can be taken into account. 

Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [3][email address] or by calling 0800
802 602.

 
Ngā mihi
 
OIA Services Team
Manatū Hauora | Ministry of Health
[4]Ministry of Health information releases 
 
 

------------------- Original Message -------------------
From: R. Kingi <[FOI #25176 email]>;
Received: Thu Dec 14 2023 10:39:22 GMT+1300 (New Zealand Daylight Time)
To: OIA Requests <[email address]>; OIA <[email address]>;
Subject: Official Information request - Risk assessment of amyloidogenic
segments by way of transfection

Dear Ministry of Health,

Several papers have been published on amyloidogenic or prionergic segments
of the sars-cov2 spike protein (e.g. "Amyloidogenesis of SARS-CoV-2 Spike
Protein", J. Am. Chem. Soc., 2022, 144, 20, 8945–8950,
[5]https://aus01.safelinks.protection.outlo...).
These epitopes also occur as a consequence of the expression the pfizer
injectable products, such as bnt162b2.

Of note is that the spike from expression of the pfizer injectable can be
detected in some individuals for quite some time (see "Detection of
recombinant Spike protein in the blood of individuals vaccinated against
SARS-CoV-2: Possible molecular mechanisms",
ProteomicsClin.Appl.2023;17:2300048,
[6]https://aus01.safelinks.protection.outlo...)

Given that, I request any internal reports, notes, communications or risk
assessments related to the expression of these amyloidogenic or prionergic
segments by way of commercial product, such as bnt162b2. 

Yours faithfully,

R. Kingi
 

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

References

Visible links
1. http://www.ombudsman.parliament.nz/
2. mailto:[email address]
3. mailto:[email address]
4. https://www.health.govt.nz/about-ministr...
5. https://pubs.acs.org/doi/10.1021/jacs.2c...
6. https://onlinelibrary.wiley.com/doi/10.1...

hide quoted sections

Link to this

From: OIA Requests


Attachment Outlook 2eru0bcb.png
80K Download

Attachment H2023034061 Response.pdf
208K Download View as HTML


Kia ora R Kingi,

 

Please find attached our response to your official information request.

 

Ngā mihi 

  

 

OIA Services Team

Manatū Hauora | Ministry of Health

M[1]inistry of Health information releases 
U[2]nite against COVID-19 

 

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

References

Visible links
1. https://www.health.govt.nz/about-ministr...
2. https://covid19.govt.nz/

hide quoted sections

Link to this

Things to do with this request

Anyone:
Ministry of Health only: